Ancillary Studies in Immunomodulation Clinical Trials (R01)

The summary for the Ancillary Studies in Immunomodulation Clinical Trials (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Ancillary Studies in Immunomodulation Clinical Trials (R01)
	CFDA Number:	93.846
	CFDA Description:	Arthritis, Musculoskeletal and Skin Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Food and Nutrition Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AI-10-014
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 18, 2010
	Creation Date:	Mar 18, 2010
	Original Closing Date for Applications:	Jun 09, 2010
	Current Closing Date for Applications:	Jun 09, 2010
	Archive Date:	Jul 10, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$2,000,000
	Federal Grant Award Ceiling:	$250,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This FOA invites R01 applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft rejection in solid organ, cell, and tissue transplantation; graft versus host disease in hematopoietic stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. This FOA is a renewal with modifications of RFA AI-08-011 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-08-011.html). In order to review and confer awards to grant applications received in response to this FOA in a timely fashion, without delay of the parent clinical trial, applications submitted in response to the FOA will be subject to an accelerated review/award process. Highly meritorious applications selected for funding under this FOA may receive their awards as early as thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly. Mechanism of Support. This FOA will utilize the NIH Research Project grant (R01) mechanism. Funds Available and Anticipated Number of Awards. The National Institute of Allergy and Infectious Diseases (NIAID) intends to commit $2 million in Fiscal Year 2010 to fund five to six applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ai-10-014.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43); • NIAMS Clinical Trial Implementation Cooperative Agreement (U01); • Support of NIAMS Program Project Grants (P01); • Multidisciplinary Clinical Research Centers (P60); • NIAMS Multi-Center Clinical Study Implementation Planning Grants (U34); • COLLABORATIVE ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES SCIENCE AWARD (CAMSSA); • NIAMS SMALL GRANT PROGRAM FOR NEW INVESTIGATORS; • SKIN DISEASES RESEARCH CORE CENTERS; • CORE CENTERS FOR MUSULOSKELETAL DISORDERS; • MICROCIRCULATION AND TARGET ORGAN DAMAGE IN RHEUMATIC AND SKIN DISEASES